Literature DB >> 11950797

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

C P Day1.   

Abstract

Although non-alcoholic steatohepatitis (NASH) was considered relatively uncommon prior to the middle of the last decade, over the past three years there has been an explosion of studies on various aspects of NASH with one study reporting that after hepatitis C, NASH was the most common diagnosis in patients presenting largely with persistent abnormalities of liver function tests. The field of NASH has come a long way in a relatively short space of time. This article considers advances in knowledge that have arisen as a result of these studies and highlights areas for further work.

Entities:  

Mesh:

Year:  2002        PMID: 11950797      PMCID: PMC1773193          DOI: 10.1136/gut.50.5.585

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

Review 1.  Treatment of nonalcoholic fatty liver: present and emerging therapies.

Authors:  P Angulo; K D Lindor
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

2.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

3.  The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects.

Authors:  T Goto; T Onuma; K Takebe; J G Kral
Journal:  Int J Obes Relat Metab Disord       Date:  1995-12

Review 4.  Mitochondria in steatohepatitis.

Authors:  D Pessayre; A Berson; B Fromenty; A Mansouri
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

5.  Metformin in non-alcoholic steatohepatitis.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; M Zoli; N Melchionda
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

6.  Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.

Authors:  M M Skelly; P D James; S D Ryder
Journal:  J Hepatol       Date:  2001-08       Impact factor: 25.083

7.  Clinical hepatology: profile of an urban, hospital-based practice.

Authors:  D Byron; G Y Minuk
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

8.  Liver in obesity.

Authors:  A Braillon; J P Capron; M A Hervé; C Degott; C Quenum
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  45 in total

1.  Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.

Authors:  Paola Loria; Amedeo Lonardo; Francesca Leonardi; Cristina Fontana; Lucia Carulli; Anna Maria Verrone; Andrea Borsatti; Marco Bertolotti; Fabio Cassani; Alberto Bagni; Paolo Muratori; Dorval Ganazzi; Francesco B Bianchi; Nicola Carulli
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

Review 2.  Cirrhosis: new research provides a basis for rational and targeted treatments.

Authors:  John P Iredale
Journal:  BMJ       Date:  2003-07-19

3.  Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8.

Authors:  Ahmed Abu Shanab; Paul Scully; Orla Crosbie; Martin Buckley; Liam O'Mahony; Fergus Shanahan; Sanaa Gazareen; Eileen Murphy; Eamonn M M Quigley
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

Review 4.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

6.  MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle.

Authors:  Shingo Takagi; Miki Nakajima; Katsuhiko Kida; Yu Yamaura; Tatsuki Fukami; Tsuyoshi Yokoi
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

Review 7.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15

Review 8.  Inflammatory mediators of hepatic steatosis.

Authors:  Elizabeth Hijona; Lander Hijona; Juan I Arenas; Luis Bujanda
Journal:  Mediators Inflamm       Date:  2010-03-16       Impact factor: 4.711

Review 9.  Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases.

Authors:  Ravindresh Chhabra; Richa Dubey; Neeru Saini
Journal:  Mol Cancer       Date:  2010-09-03       Impact factor: 27.401

10.  Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.

Authors:  Giulia Vecchione; Elena Grasselli; Adriana Voci; Francesca Baldini; Ignazio Grattagliano; David Qh Wang; Piero Portincasa; Laura Vergani
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.